There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market.
Misery loves company, and so it goes with the stock market for the innovation ecosystem these days.
Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what caused the carnage.
In December 2019, I was in London meeting with my future co-founders to discuss an asset that would eventually become the cornerstone of a virtual drug development company. At that time, Kinaset Therapeutics, Inc. as it would become, had negotiated terms to in-license an asset from a UK based company that was changing its strategy. With terms agreed and a period of exclusivity in hand, the plan was to launch a private fundraising on the heels of JP Morgan in January 2020.
By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC.
No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely play a key role in solving some of the biggest healthcare challenges we face today. In fact, it is already doing that by revolutionizing drug discovery, clinical research, and several other aspects of pharmaceutical R&D.
By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC.